|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
<b>Abbreviations:</b> AAP: American Academy of Pediatrics; BMI: body mass index; BP: blood pressure; cm: centimeter; DBP: diastolic blood pressure; HT: hypertension; kg: kilograms; m: meter; NHANES: National Health and Nutrition Examination Survey; ROC: receiver operating characteristic curve; SBP: systolic blood pressure; SBPHR: systolic blood pressure-to-height ratio; SD: standard deviation; WC: waist circumference; WHR: waist-to-height ratio.
|
31038015 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg or currently taking antihypertensive medicines.
|
29553846 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg, or current hypertension treatment, and was age-standardized to WHO world population.
|
30308598 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
AlteredExpression |
BEFREE |
High blood pressure levels at 10 gestational weeks significantly increased the risk of SGA birth (SBP: RR = 1.32, 95% CI: 1.11-1.56; DBP: RR = 1.10, 95% CI: 1.05-1.14).
|
30631132 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg, or current hypertension treatment, and was age-standardized to WHO world population.
|
30817448 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was measured as SBP at least 140 mmHg or DBP at least 90 mmHg.Random-effects meta-analysis was used.
|
31166251 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Hypertension was defined as SBP at least 130 mmHg or DBP at least 80 mmHg, taking antihypertensive medicine or self-report.
|
31356404 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
SBP control rate among women with hypertension was the highest in 40-49 years (67.0%) but without linear trend by age group.
|
31190479 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
A linear relationship was revealed between intradialytic SBP in IDH patients, indicating that the pre-HD and intra-HD SBP were correlated with post-HD SBP.
|
30325241 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
According to three independent measurements of SBP in 1987, 1989, and 1992, cases of the same age and sex with continuous SBP at least 75 percentile were classified as the high-blood pressure (BP) group, whereas those with SBP less than 50 percentile were classified as the normal-BP group.
|
28060189 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Achievement of target SBP without attention to decrease in DBP can increase cardiovascular morbidity in treated arterial hypertension: the Campania Salute Network.
|
31205199 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
AlteredExpression |
BEFREE |
Adjusted multiple linear regression models elicited positive associations of age (βa = 0.152, p = 0.001) and duration of hypertension (βa = 0.132, p = 0.003) with achieved level of SBP as well as BMI (βa = 0.135, p = 0.002) with DBP.
|
28129402 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
After 1 month, superior SBP (-3.1 mmHg, P = 0.02) and DBP (-2.8 mmHg, P < 0.001) reductions were observed with perindopril/indapamide/amlodipine, which were even more pronounced after excluding white-coat effect in the sustained hypertension population (-5.3/-3.7 mmHg).
|
28306636 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
After adjusted for traditional risk factors including brachial SBP, both central SBP, and AIx@75 remained significantly associated with CVD, with odds ratio and 95% confidence interval of 1.09 (1.08-1.31) and 1.20 (1.15-1.42), respectively.Diabetic patients with hypertension, ageing, male gender, and presence of CVD are independent risk factors of central BP increase; and increased central SBP and AIx@75 are significantly associated with CVD.
|
29049227 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
After Bonferroni correction the polymorphism rs4680 (ValMet) in COMT was significantly associated with lower SBP in participants treated with CCBs (P = .009) with an especially strong impact in elderly individuals (age ≥ 70) alone (Δ = -14.08 mm Hg, P = .0005).These results underline the important role of estrogens and catecholamines in hypertension and the importance of genotype dependent, age-related adjustments of calcium-channel blocker treatment.
|
28746172 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
After stratifying the subjects according to blood pressure and blood glucose, the positive relationship between RHR and UACR remained in the subjects with normal blood pressure and normal glucose tolerance, while in the hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) group and the diabetic mellitus (FPG ≥ 7.0 mmol/L and/or PPG ≥ 11.1 mmol/L) group, the relationship disappeared.
|
31534974 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82).
|
31672364 |
2020 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Asian people with hypertension: SBP: MD -7.75 mmHg (95% CI:-11,44 to -4.07; P < 0.0001) nine studies, 501 participants; DBP: MD -2.68 mmHg (95% CI: -4.21 to -1.15; P = 0.0006).
|
28391629 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Childhood hypertension and elevated blood pressure were defined as SBP and/or DBP ≥95th and ≥90th age- and gender-specific percentile, respectively.
|
31826379 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Chronic VNS therapy slowed the progression of HTN through an attenuation of SBP and by preserving HRV.
|
30766489 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Cox proportional hazards regression revealed that SBP (1.02[1.01, 1.02]) and more insomnia symptoms (1.11[1.01, 1.21]) were significant predictors of hypertension for all age groups.
|
30742871 |
2019 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
Despite having higher renal expression of <i>Nlrp3, Casp-1</i> and <i>Il-1β</i>, Ang II-induced hypertension (SBP: 139±7 mmHg) was unaffected by co-infusion of the NLRP3 inflammasome inhibitor, MCC950 (10 mg/kg/d; SBP: 145±10 mmHg).
|
28659507 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Distinguishing trajectories allows identification of subgroups at risk of hypertension and cardiovascular disease later in life and in addition can inform the design of targeted interventions to attenuate high SBP and DBP trajectories over time and maintain normal trajectories.
|
28234673 |
2017 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
GeneticVariation |
BEFREE |
Each interquartile increment in walkability was associated with the lower blood pressure outcomes of DBP (β = -0.358, 95% CI: -0.42, -0.29 mmHg), SBP (β = -0.833, 95% CI: -0.95, -0.72 mmHg) as well as reduced hypertension risk (RR = 0.970, 95% CI: 0.96, 0.98).
|
29398408 |
2018 |
|
SELENBP1
|
Hypertensive disease
|
0.100 |
Biomarker |
BEFREE |
EMPOWER-H also significantly reduced both office and home SBP and DBP, decreased office-measured weight and consumption of high-salt and high-fat foods (all P<.005), and increased intake of fruit and vegetables, minutes of aerobic exercise, and hypertension knowledge (all P<.05).
|
28928111 |
2017 |